{"id":84273,"date":"2026-06-15T03:46:11","date_gmt":"2026-06-15T03:46:11","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/84273\/"},"modified":"2026-06-15T03:46:11","modified_gmt":"2026-06-15T03:46:11","slug":"novartis-says-rare-muscle-disease-drug-shows-promise-in-early-trial","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/84273\/","title":{"rendered":"Novartis says rare muscle disease drug shows promise in early trial"},"content":{"rendered":"<p class=\"mb-4 text-lg md:leading-8 break-words\">June 11 (Reuters) &#8211; Novartis said on Thursday an experimental drug, which it \u200cacquired as part of its $12 \u200cbillion takeover of Avidity, showed promise in an \u200bearly-to-mid-stage study in patients with a type of genetic muscle disorder characterized by slowly progressive muscle weakness.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">\u2022 The Swiss drugmaker \u200csaid the \u2060drug, known as del-brax, lowered two blood markers linked to the \u2060disease and showed reduced signs of muscle damage in patients with facioscapulohumeral \u200bmuscular dystrophy.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">\u2022 \u200bNovartis said the \u200bdrug shows potential \u200cto become the first disease-modifying treatment for FSHD, which can cause weakness in the face, shoulders, arms and other muscles.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">\u2022 The company estimates it affects about \u200c45,000 to 87,000 people \u200bin the U.S. \u200band EU.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">\u2022 The \u200bdrug&#8217;s safety profile was \u200cconsistent with previous results, the \u200bcompany said.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">\u2022 \u200bNovartis plans to discuss the data with health regulators around the \u200bworld, while \u200ca late-stage study of the drug \u200bis currently enrolling patients.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">(Reporting by Kunal \u200bDas in Bengaluru)<\/p>\n","protected":false},"excerpt":{"rendered":"June 11 (Reuters) &#8211; Novartis said on Thursday an experimental drug, which it \u200cacquired as part of its&hellip;\n","protected":false},"author":2,"featured_media":84274,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[13808,7997,43045,206],"class_list":["post-84273","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-avidity","tag-experimental-drug","tag-muscle-disorder","tag-novartis"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116752075025189745","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/84273","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=84273"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/84273\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/84274"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=84273"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=84273"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=84273"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}